stockrow
Friday 6 November 2026
Export FTH’s income statement to Excel — free account
Faeth Therapeutics, Inc.
- EPS
- +78.2%
- Free cash flow
- −262.7%
Quarter to September 2026, against a year earlier
21.86
1.94
+9.74%
Follow FTH
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Sep ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | — | — | — | — | 6 | 6 | 6 | 0.0% | |
| Gross margin, % | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — | 0.00 | 0.0 pt | ||||||
| EBT | — | — | (13) | (17) | (20) | (37) | (49) | (34) | (30) | (21) | (211) | +7.1% | ||||||
| EBT margin, % | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 pt | ||||||
| Net income | — | 0 | (13) | (17) | (20) | (37) | (49) | (34) | (30) | (21) | (211) | n/m | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | n/m | |||||
| Earnings | — | — | (0.57) | (1,118.47) | (250.60) | (26.60) | (31.60) | (24.40) | (24.00) | (16.72) | (138.82) | +62.0% | ||||||
| Cash flow | — | — | (0.35) | (466.63) | (219.66) | (21.84) | (25.42) | (22.91) | (19.64) | (16.22) | (1.67) | +72.9% | ||||||
| Capex | — | — | 0.00 | (2.89) | (14.96) | (1.23) | (0.20) | (0.01) | (0.12) | 0.19 | 0.00 | n/m | ||||||
| Free cash flow | — | — | (0.35) | (469.51) | (234.63) | (23.07) | (25.62) | (22.92) | (19.76) | (16.03) | (1.67) | +72.6% | ||||||
| Book value | — | — | (0.20) | (3,738.14) | (700.29) | 105.74 | 67.36 | 46.43 | 30.56 | 14.74 | 6.23 | n/m | ||||||
| Shares, m | — | — | 29 | 0 | 0 | 1 | 2 | 1 | 1 | 1 | 9 | (36.2%) | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | — | 0 | — | |||||
| P/S | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| P/B | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| EV/Sales | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| EV/FCF | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | — | — | (10) | (9) | (18) | (30) | (39) | (32) | (25) | (20) | (43) | +10.3% | |||||
| Capex | — | — | 0 | 0 | (1) | (2) | 0 | 0 | 0 | 0 | 0 | n/m | ||||||
| Free cash flow | — | — | (10) | (9) | (19) | (32) | (39) | (32) | (25) | (20) | (43) | +10.1% | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | — | — | (1) | (21) | 15 | 144 | 100 | 62 | 36 | 17 | 167 | n/m | |||||
| Net debt | — | — | 4 | 16 | (16) | (146) | (106) | (65) | (41) | (21) | (175) | n/m | ||||||
| Shareholders’ equity | — | — | (6) | (69) | (56) | 147 | 103 | 65 | 38 | 19 | 161 | n/m | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | — | — | (1,820.86) | (1,339.68) | (178.44) | (42.13) | (35.78) | (35.38) | (50.37) | (61.78) | (204.67) | +1,759.1 pt | |||||
| ROIC | — | — | 0.00 | 0.00 | 0.00 | (4,138.91) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 pt | ||||||
| ROE | — | — | 27.58 | 33.64 | 32.30 | (81.70) | (38.88) | (40.52) | (58.40) | (74.01) | (229.61) | (101.6) pt | ||||||
| People | ||||||||||||||||||
| People | Employees | — | — | — | — | 32 | 56 | 28 | 27 | 15 | 23 | — | (6.4%) | |||||
| Revenue/emp, $m | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | n/m | ||||||
Negative figures in brackets.
estimates
Fundamentals updated 5 Nov 2026
Faeth Therapeutics, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| CYVNY Ceryvyn Therapeutics Ltd. - Unsponsored ADR | $524.8M | — (loss-making) | — (loss-making) | −7.53% (below 0%: shrinking) | n/m | −31.52% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| ENTX Entera Bio Ltd. | $520.0M | — (loss-making) | — (loss-making) | +200.00% (above 0%: growing) | n/m | −108.86% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| FTH Faeth Therapeutics, Inc. | $514.8M | — (loss-making) | — | — | n/m | −262.66% (below 0%: shrinking) | 0.00% | 0.00% | |
| NGNE Neurogene Inc. | $513.3M | — (loss-making) | — (loss-making) | — | n/m | −22.97% (below 0%: shrinking) | 100.00% | 0.00% | Compare |
| CLYM Climb Bio, Inc. | $509.5M | — (loss-making) | — | — | n/m | +3.73% (above 0%: growing) | — | 0.00% | Compare |
| YDES YD Bio Limited | $508.7M | — | — | — | — | — | — | — | Compare |
| SLBT SL SCIENCE HLDG | $504.7M | — | — | — | — | — | — | — | Compare |
| PBYI Puma Biotechnology, Inc. | $504.3M | 15.3× | 24.2× | +7.75% (above 0%: growing) | +33.33% (above 0%: growing) | −88.45% (below 0%: shrinking) | 77.92% | 13.42% | Compare |
| OVID Ovid Therapeutics | $503.9M | — (loss-making) | — (loss-making) | +463.85% (above 0%: growing) | n/m | −268.54% (below 0%: shrinking) | 100.00% | (2,141.61%) | Compare |
| Median of peers | $509.1M | — | — | +103.88% | — | −59.98% | 77.92% | 0.00% |
Pay and ownership Proxy statement filed 27 April 2026
Ownership
Directors and executive officers, together
7.00%
H&S Investments I LP
16.60%
Cambrian BioPharma Inc.
11.60%
Trails Edge Capital Partners
9.30%
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more.
Read the proxy statement